Loading, Please Wait...
Clinical Stage Cancer Immunotherapy Biotechnology Company Files Patent Expanding Uses of its Pterostilbene Based Product Pipeline
OCEANSIDE, Calif., Aug. 13, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced today filing of a patent on recent data showing pterostilbene potently augments killing of breast cancer, prostate cancer, and ovarian cancer cells by ozone therapy.
The data are an extension of ongoing work at the Company seeking to identify means of enhancing the effects of pterostilbene administration for treatment of a variety of cancers, as well as enhancing the efficacy of existing cancer therapies.
Previously the Company has been granted United States Patent # 9,682,047 covering augmentation of immunotherapy efficacy using pterostilbene administration. Furthermore, the Company has developed NanoStilbene, a nanotechnology-based product that enhances optimal delivery of pterostilbene to tissue. In the current patent application, administration of ozone in conjunction with various concentrations of pterostilbene resulted in enhanced tumor cell killing, without killing of control, non-cancer cells.
"The ability of ozone gas to possess a selective ability to kill cancer cells compared to non-cancer cells has been known since the 1980 publication by Sweet et al in the prestigious peer-reviewed journal Science1. Furthermore, peer-reviewed studies have demonstrated that ozone therapy can enhance cancer-killing effects of chemotherapy2," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "By demonstrating potentiation of the cancer-killing effects of ozone therapy by pterostilbene, we anticipate initiating collaborations with international doctors studying the efficacy of this modality in the treatment of cancer."
Therapeutic Solutions International has performed clinical pharmacokinetic studies using NanoStilbene to deliver pterostilbene. The concentrations of pterostilbene that are found in the blood 4 hours after oral administration of NanoStilbene are sufficient to enhance the cancer-killing effect of ozone therapy based on data presented in the patent application.
"Pterostilbene is known to kill cancer cells in part through increasing endoplasmic reticulum stress selectively in tumors and not in healthy cells3. Our hypothesis was that ozone therapy may alter endoplasmic reticulum-associated molecular pathways, and thus a synergistic effect may be observed," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "By understanding molecular mechanisms of 'alternative medicines' such as ozone therapy, we can identify ways of leveraging their effects and developing therapeutic approaches that have higher chances of success."
"Numerous physicians internationally are using ozone therapy and other means of oxidative medicine to treat chronic illness. Although techniques such as autohemotherapy have a very strong safety record, little work is being conducted at elucidating mechanisms of action and identifying ways of integrating these approaches into conventional cancer care," said Dr. Juergen Winkler, Member of the Company's Scientific Advisory Board and Medical Director of Quantum Functional Medicine. "The medical doctors and scientists at Therapeutic Solutions International are leading the way in developing scientific understanding for molecular mechanisms of alternative medical immunotherapies in an objective and rigorous manner. By combining alternative medicine with cutting edge science, I am eager to watch the proper clinical trial translation that TSOI has performed in taking these concepts from bench to bedside."
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is www.therapeuticsolutionsint.com.
1 Sweet et al. Ozone selectively inhibits growth of human cancer cells. Science. 1980 Aug 22;209(4459):931-3. https://www.ncbi.nlm.nih.gov/pubmed/7403859
2 Zanker et al. In vitro synergistic activity of 5-fluorouracil with low-dose ozone against a chemoresistant tumor cell line and fresh human tumor cells. Chemotherapy. 1990;36(2):147-54. https://www.ncbi.nlm.nih.gov/pubmed/2311442
3 Papandreou et al. Plant stilbenes induce endoplasmic reticulum stress and their anti-cancer activity can be enhanced by inhibitors of autophagy.Exp Cell Res. 2015 Nov 15;339(1):147-53. https://www.ncbi.nlm.nih.gov/pubmed/26477823
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Therapeutic Solutions International, Inc.